Emma Andrus, Associate Editor

The average pain score reported during treatment was 0.4/10, according to a poster presented at the SPD's annual meeting.

Mancini discusses his SPD 2024 lecture, emphasizing off-label treatments, surrogate diagnostic markers, simpler therapies, and the importance of empathy and education.

In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on advancements in their careers.

The conference aimed at providing pediatric dermatology clinicians with the latest in the specialty begins tomorrow in Toronto, Ontario.

Ahead of the SPD's Annual Meeting in Toronto, share with us: What do you hope to learn?

Preoperative pain and anticipated postoperative pain were found to predict postoperative pain in patients undergoing dermatologic surgery.

Lawrence Eichenfield, MD, provides insights into the clinical implications of topical ruxolitinib cream for atopic dermatitis and treatment patterns.

Explore dermatology's history and the journey through our publication's 45 years of covering an ever evolving specialty.

July 8th has been established as World Skin Health Day, with celebrations planned and anticipated on a global scale.

Matthew Zirwas, MD, hosted a Case-Based Roundtable discussion to review 2 challenging cases of atopic dermatitis involving intense itch and severe hand dermatitis.

Some patients may be looking for alternatives to BPO, questioning its safety.

Keep up with the latest headlines in dermatology from the past week, including the appointment of the Canadian Dermatology Association's new president, a program aimed at supporting diverse, aspiring dermatologists, and more.

In case you missed it, this week we had news about the FDA's approval of biosimilar ustekinumab-ttwe, addressing acne scarring concerns, the intersection of permanent makeup and dermatology, and more.

Adewole Adamson, MD, MPP, discusses the Environmental Working Group's 2024 Guide to Sunscreens and what clinicians should discuss with patients who express concerns with the headlines stemming from the report.

As many as 76.5% of participants could not name any psychodermatology resources, while only 58.8% were definitively interested in training on the topic.

Iain Stuart, PhD, discusses VYN202's status and potential in psoriasis and immuno-inflammatory diseases.

Biofrontera's red light source is approved for use in combination with aminolevulinic acid hydrochloride (Ameluz) topical gel, 10%.

Recent research and conversations shared at the National Eczema Association expo tackled the link between patient well-being and eczema.

Pyzchiva will be commercialized by Sandoz in the United States.

Dermatology Times asked our readers to share what conferences they are looking forward to in the third quarter of 2024.

Keep up with the latest headlines in dermatology from the past week, including application of AI in dermatology, exposure to forever chemicals through the skin, and more.

Risankizumab outperformed other biologics in real-world psoriasis treatment, achieving higher PASI 90/100 rates and patient satisfaction.

Dermatology Times is looking back on the top stories in dermatology from the month of June.

Dermatology Times is recapping our top expert interviews from the month of June.

Bradley Burnam discusses results from an in-vivo model of atopic dermatitis.

Recent research has shed light on public interest of BPO utilizing relative search volume data.

Ensemble No.2, or ENS-002, is an investigational live biotherapeutic product first detected by Concerto Biosciences using its kChip technology.

The study found that CMT is effective and well-tolerated in treating stable vitiligo, with significant positive correlations between the target area treatment ratio and repigmentation.

Authorization for Eli Lilly's Ebglyss is based on positive results from the ADvocate 1, ADvocate 2, and ADhere studies.

The study found a genetic link between vitiligo and autoimmune thyroid diseases, but no similar link with autoimmune hepatitis or Graves' disease.